(1r,4r)-4-(fluoromethyl)cyclohexanecarbonyl chloride | 1115331-03-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: (1r,4r)-4-(fluoromethyl)cyclohexanecarbonyl chloride
• CAS: 1115331-03-7
• 化学式: C₈H₁₂ClFO
• 分子量: 178.634
• InChiKey: BCUOBTHSSHCIKS-LJGSYFOKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  11.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  17.07
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  methyl 5-(3,3-dimethylbut-1-ynyl)-3-(isopropylamino)thiophene-2-carboxylate 、 (1r,4r)-4-(fluoromethyl)cyclohexanecarbonyl chloride 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection

  摘要：

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

  DOI：

  10.1021/jm401420j
• 作为产物：
  描述：

  (1r,4r)-methyl 4-(hydroxymethyl)cyclohexanecarboxylic acid 在 [双(2-甲氧基乙基)胺]三氟化硫 、 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 (1r,4r)-4-(fluoromethyl)cyclohexanecarbonyl chloride
  参考文献：
  名称：

  Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection

  摘要：

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

  DOI：

  10.1021/jm401420j

文献信息

• [EN] VIRAL POLYMERASE INHIBITORS<br/>[FR] INHIBITEURS DE POLYMERASE VIRALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009018656A1

  公开（公告）日：2009-02-12

  Compound of Formula I: wherein, R2, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase

  化合物的化学式I：其中，R2、R5和R6如本文所定义，可用作乙型肝炎病毒NS5B聚合酶的抑制剂。
• VIRAL POLYMERASE INHIBITORS
  申请人：Beaulieu Pierre L.

  公开号：US20100286131A1

  公开（公告）日：2010-11-11

  Compounds of formula I: wherein, R 2 , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.